Current ART

DRUG3 trials

Sponsors

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia, The University of Texas Health Science Center, Houston

Conditions

HIVHIV InfectionsHIV-1 Infection

Phase 3

Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY

CompletedNCT03029689

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaHIV

Start: 2017-07-28End: 2020-04-30Updated: 2025-06-17

Phase 4

(mo)BETTA Trial in Transwomen for Optimization of ART

TerminatedNCT03348163

The University of Texas Health Science Center, HoustonHIV Infections

Start: 2018-06-06End: 2020-12-15Updated: 2022-10-03

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

CompletedNCT03683524

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaHIV-1 Infection

Start: 2018-11-19End: 2021-08-10Updated: 2022-04-01

Related Papers

A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes

Open Forum Infectious Diseases2023-10-314 citations